These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33207141)

  • 1. Persistence and Adherence of Anticholinergics and Beta-3 Agonist for the Treatment of Overactive Bladder: Systematic Review and Meta-Analysis, and Network Meta-Analysis.
    Song YS; Lee HY; Park JJ; Kim JH
    J Urol; 2021 Jun; 205(6):1595-1604. PubMed ID: 33207141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study.
    Park JS; Choi SB; Jang WS; Kim J; Ham WS
    Eur Urol Focus; 2024 Mar; 10(2):306-314. PubMed ID: 38388215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
    Welk B; McArthur E
    BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada.
    Minhas R; Tadrous M; Elterman D; Gomes T
    Neurourol Urodyn; 2018 Jun; 37(5):1693-1700. PubMed ID: 29682790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: Retrospective analysis of a UK General Practice prescription database.
    Wagg AS; Foley S; Peters J; Nazir J; Kool-Houweling L; Scrine L
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28906080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder.
    Illiano E; Finazzi Agrò E; Natale F; Balsamo R; Costantini E
    Int Urol Nephrol; 2020 Jun; 52(6):1035-1042. PubMed ID: 32086713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.
    Kato D; Uno S; Van Schyndle J; Fan A; Kimura T
    Int J Urol; 2017 Oct; 24(10):757-764. PubMed ID: 28833621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
    Sussman D; Yehoshua A; Kowalski J; Lee W; Kish J; Chaudhari S; Murray B
    Int J Clin Pract; 2017 Mar; 71(3-4):. PubMed ID: 28371019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy for an overactive bladder.
    Thiagamoorthy G; Cardozo L; Srikrishna S
    Womens Health (Lond); 2015 Jul; 11(4):445-8. PubMed ID: 26238677
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient utilization survey of mirabegron prescribed for overactive bladder.
    Rahkola-Soisalo P; Balcerzak M; Ruotsalainen J; Mikkola TS
    Investig Clin Urol; 2019 Mar; 60(2):114-119. PubMed ID: 30838344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice.
    Shin JH; Choo MS
    Low Urin Tract Symptoms; 2019 May; 11(3):151-157. PubMed ID: 30623583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Adv Ther; 2024 May; 41(5):2086-2097. PubMed ID: 38520502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from the Norwegian Prescription Database.
    Mauseth SA; Skurtveit S; Spigset O
    Acta Obstet Gynecol Scand; 2013 Oct; 92(10):1208-15. PubMed ID: 23763552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients.
    Krhut J; Gärtner M; Petzel M; Sykora R; Nemec D; Tvrdik J; Skoupa J
    Scand J Urol; 2014 Feb; 48(1):79-83. PubMed ID: 23870042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study.
    Martan A; Masata J; Krhut J; Zachoval R; Hanus T; Svabik K
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():247-250. PubMed ID: 28073038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis.
    Sartori LGF; Nunes BM; Farah D; Oliveira LM; Novoa CCT; Sartori MGF; Fonseca MCM
    Rev Bras Ginecol Obstet; 2023 Jun; 45(6):337-346. PubMed ID: 37494577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.